Tenderwize
Retour à la recherche

Open House Discount Agreements for Icatibant

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Mar 31, 2027 · 162 days left·Open·Supplies
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Icatibant, ATC B06AC02

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

30 / 100

Facteurs de risque

No estimated value or minimum purchase commitment; revenue uncertainty. Buyer may replace open-house with exclusive con...

Strict proof of marketability required; incomplete documentation may delay or prevent participation.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Informations clés

Pouvoir adjudicateur
AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse
Pays
Allemagne
CPV
33600000 - Pharmaceutical products
Date limite
Mar 31, 2027

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Conclusion of non-exclusive discount agreements for Icatibant (ATC B06AC02) medicinal products.
  • Contracts valid from June 2025 to May 2027 with rolling monthly entry.
Afficher le résumé complet

This is an Open House (non-exclusive) discount agreement procedure for the active ingredient Icatibant (ATC B06AC02) organized by AOK Rheinland-Pfalz/Saarland. It is not a public procurement under EU Directive 2014/24 but published for transparency. All pharmaceutical companies can join under uniform terms from June 2025 to May 2027, with monthly entry possible. Estimated value is not provided. Only one lot exists. No procurement documents were analyzed, only the notice itself.

Risques

No estimated value or minimum purchase commitment; revenue uncertainty. Buyer may replace open-house with exclusive con...

Strict proof of marketability required; incomplete documentation may delay or prevent participation.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical company (pharmazeutischer Unternehmer) with authorized and marketable medicines in Germany.
  • Medicines must be listed in Lauer-Taxe as marketable or provide proof via AMIce database extracts.
  • Children's medicines (according to BfArM list) are excluded.

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria specified; open-house model with uniform terms for all participants.

Acheteur

Localisation

Eisenberg, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE271900642

Activité

Health

Lots (1)

LOT-0001

Open House Discount Agreements for Icatibant

Non-exclusive discount agreements for pharmaceutical products containing Icatibant (ATC B06AC02). Contracts last maximum 24 months, ending no later than 31.05.2027. Entry possible on the first of each month. The buyer may replace open-house contracts with exclusive contracts from competitive procedures. Children's medicines according to BfArM list are excluded.

SuppliesEU fundedElectronic submission

Localisation

Eisenberg, Germany

Durée

May 2025 - May 2027

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria specified; open-house model with uniform terms for all participants.

Date limite

Deadline Mar 31, 2027

Détails de la procédure

Date de publication
10 Apr 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
235827-2025

Documents (1)

Appels d'offres similaires